Mayne Pharma Group Limited (ASX:MYX)

Australia flag Australia · Delayed Price · Currency is AUD
5.02
+0.12 (2.45%)
Jun 6, 2025, 4:10 PM AEST
1.83%
Market Cap 398.10M
Revenue (ttm) 413.53M
Net Income (ttm) -129.23M
Shares Out 81.25M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 619,202
Average Volume 1,505,002
Open 4.99
Previous Close 4.90
Day's Range 4.96 - 5.10
52-Week Range 3.74 - 7.31
Beta 1.08
RSI 40.63
Earnings Date May 27, 2025

About Mayne Pharma Group

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease the... [Read more]

Sector Healthcare
Founded 2005
Employees 967
Stock Exchange Australian Securities Exchange
Ticker Symbol MYX
Full Company Profile

Financial Performance

Financial Statements

News

Cosette terminates $672m Mayne Pharma deal as legal challenge looms

The private-equity backed American giant began reviewing the deal two weeks ago because of concerns about its target’s financial performance since it first bid.

2 days ago - The Australian Financial Review

Why a private equity group is rethinking its bid for Mayne Pharma

Triggering a material adverse change clause is rare in M&A. It’s why Mayne should release Cosette’s letter on why it is reviewing its $672m bid.

16 days ago - The Australian Financial Review

Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal

Shares of Mayne Pharma plunged 30% on Wednesday after U.S.-based Cosette Pharmaceuticals initiated a review of its A$672 million ($432.1 million) acquisition, citing a "material adverse change" in the...

16 days ago - Reuters

Mayne Pharma shares crash after suitor Cosette raises concerns

Shares in the drug company fell 30 per cent on Wednesday after its takeover suitor said there had been a material adverse change in its performance.

16 days ago - The Australian Financial Review

Mayne Pharma shares crash after suitor Cosette threatens to walk

Shares in the drug company fell 30 per cent on Wednesday after its takeover suitor said there had been a material adverse change in its performance.

16 days ago - The Australian Financial Review

ASX 200 LIVE: Mayne Pharma shares plunge; CBA hits record; JHX sales, earnings slip amid AZEK buy; ASIC sues Resimac, sharemarket rises

Shares lift; CBA resets intraday record, tops $176; Mayne Pharma-Cosette tie-up hangs in balance; Nufarm plunges; James Hardie drops 5pc. Follow live.

16 days ago - The Australian Financial Review

Disclosure doozy makes a mockery of Australia’s safe-haven fantasy

If you told a private-equity suitor about a regulatory headache, but not shareholders, was the event disclosable or not? A 15 per cent share price drop says Mayne Pharma got this one wrong.

22 days ago - The Australian Financial Review

Mayne Pharma Group reports 1H results

3 months ago - Seeking Alpha

Mayne Pharma Group Ltd (MAYNF) (H1 2025) Earnings Call Highlights: Strong Growth in Women's ...

Mayne Pharma Group Ltd (MAYNF) (H1 2025) Earnings Call Highlights: Strong Growth in Women's Health Boosts Revenue and Profitability

3 months ago - GuruFocus

Mayne Pharma expects earnings to triple, shares jump 24pc

Shares in volatile drugmaker Mayne Pharma jumped 24 per cent on Monday after the company said it expected stronger first-half earnings and revenues.

4 months ago - The Australian Financial Review

FEDERAL CONTRACEPTION PROPOSAL TO EXPAND ACCESS AND AFFORDABLE COVERAGE PAVES A STRONGER PATH FOR MAYNE PHARMA'S GROWTH IN WOMEN'S HEALTH

Proposed Ruling Aims to Eliminate Out-of-Pocket Costs for Contraception, Enhancing Access for Women in the United States ADELAIDE, Australia and RALEIGH, N.C. , Nov. 4, 2024 /PRNewswire/ -- Mayne Phar...

7 months ago - PRNewsWire

Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement

Mayne Pharma has filed a patent infringement lawsuit against Indian drugmaker Sun Pharma in a U.S. court, the Australian drugmaker said on Thursday.

11 months ago - Reuters

Mayne Pharma Group Limited (MAYNF) Q2 2024 Earnings Call Transcript

Mayne Pharma Group Limited (OTCPK:MAYNF) Q2 2024 Results Conference Call February 25, 2024 5:00 PM ET

1 year ago - Seeking Alpha